TY - JOUR
T1 - Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy
T2 - Retrospective observation study
AU - Takayama, Kei
AU - Kaneko, Hiroki
AU - Kataoka, Keiko
AU - Hattori, Kyoko
AU - Ra, Eimei
AU - Tsunekawa, Taichi
AU - Fukukita, Hiroshi
AU - Haga, Fuminori
AU - Ito, Yasuki
AU - Terasaki, Hiroko
N1 - Publisher Copyright:
© 2017 Takayama et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2017/5
Y1 - 2017/5
N2 - Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with nave PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with nave PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both P < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both P < 0.05) but not in the IAI group. A mean of 3.7 ± 0.9 and 5.6 ± 2.0 injections was administered to the combination and IAI groups, respectively (P = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.
AB - Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with nave PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with nave PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both P < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both P < 0.05) but not in the IAI group. A mean of 3.7 ± 0.9 and 5.6 ± 2.0 injections was administered to the combination and IAI groups, respectively (P = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.
UR - https://www.scopus.com/pages/publications/85018763386
UR - https://www.scopus.com/pages/publications/85018763386#tab=citedBy
U2 - 10.1371/journal.pone.0176100
DO - 10.1371/journal.pone.0176100
M3 - Article
C2 - 28467427
AN - SCOPUS:85018763386
SN - 1932-6203
VL - 12
JO - PloS one
JF - PloS one
IS - 5
M1 - e0176100
ER -